Edition:
United Kingdom

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

1.18USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.18
Open
$1.24
Day's High
$1.24
Day's Low
$1.15
Volume
9,721
Avg. Vol
30,760
52-wk High
$10.18
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

Achieve qtrly loss per share $0.90‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Achieve Life Sciences Inc ::Achieve reports financial results for third quarter 2017.Achieve Life Sciences Inc qtrly loss per share $0.90‍​.  Full Article

Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Sopharma Ad <3JR.BB>:Achieve Life Sciences -‍ co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets​.Achieve Life Sciences Inc - ‍exclusive license agreement provides supply of Cytisine to co for up to 20 years​.Achieve Life Sciences Inc - ‍sopharma agrees to produce CGMP-grade Cytisine for achieve's use in development and commercialization of Cytisine​.  Full Article

ACHIEVE LIFE SCIENCES COMMENCES ADVANCEMENT OF CYTISINE CLINICAL DEVELOPMENT PROGRAM
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES INC - ANNOUNCES COMMENCEMENT OF A MULTI-DOSE STUDY TO EVALUATE BOTH PK AND PD CHARACTERISTICS OF CYTISINE.ACHIEVE LIFE SCIENCES INC - ‍MULTI-DOSE PK/PD STUDY EXPECTED TO BE COMPLETED BY END OF YEAR, WITH DATA EXPECTED BY FIRST-QUARTER OF 2018​.ACHIEVE LIFE SCIENCES-‍DATA ANALYSIS ONGOING,RESULTS EXPECTED BY END OF YEAR IN STUDY FOR EVALUATING EFFECT OF FOOD ON BIOAVAILABILITY OF 3MG CYTISINE​.  Full Article

Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences as of Aug 1
Friday, 11 Aug 2017 

Aug 11 (Reuters) - Robert Schacter :Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences Inc as of August 1, 2017 - SEC filing‍​.  Full Article

Oncogenex says will cut about 55 pct of company's workforce
Friday, 28 Oct 2016 

Oncogenex Pharmaceuticals Inc : Oncogenex - on October 25, 2016, committed to a restructuring of a portion of company's workforce . Oncogenex Pharmaceuticals Inc - currently anticipates incurring total restructuring costs of approximately $1.4 million . Oncogenex Pharmaceuticals Inc says expects restructuring to be substantially complete in Q1 of 2017 . Oncogenex Pharmaceuticals - as part of restructuring, will eliminate 16 positions, representing approximately 55 pct of the company’s workforce .Oncogenex Pharmaceuticals- continuing to review potential impact of restructuring, is unable to estimate additional restructuring costs at this time.  Full Article

Oncogenex's Phase 3 trial of Custirsen in men did not meet primary endpoint
Tuesday, 16 Aug 2016 

Oncogenex Pharmaceuticals Inc : Oncogenex announces results from the phase 3 affinity trial of custirsen in men with metastatic castrate-resistant prostate cancer . To initiate discussions with U.S. Food and drug administration to evaluate options related to an early analysis of phase 3 enspirit trial . Trial did not meet primary endpoint . Adverse events were consistent with those observed in previous trials of custirsen in metastatic crpc .Engaged MTS Health Partners, Lp as its advisor to assist with exploration of strategic alternatives.  Full Article

Oncogenex Pharma Q2 revenue $2.1 million vs est $1.2 million
Thursday, 4 Aug 2016 

Oncogenex Pharmaceuticals Inc : Oncogenex pharmaceuticals, inc. Reports financial results for second quarter 2016 . Q2 revenue $2.1 million .Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.  Full Article

Oncogenex Pharmaceuticals qtrly loss per share $0.12
Thursday, 12 May 2016 

Oncogenex Pharmaceuticals Inc : Qtrly loss per share $0.12 . Oncogenex pharmaceuticals, inc. Reports financial results for first quarter 2016 . Q1 revenue $2.9 million .Q1 revenue view $4.1 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Achieve qtrly loss per share $0.90‍​

* Achieve Life Sciences Inc qtrly loss per share $0.90‍​ Source text for Eikon: Further company coverage: